ProfileGDS5678 / 1424628_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 97% 96% 97% 97% 97% 96% 97% 97% 97% 97% 97% 96% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.157897
GSM967853U87-EV human glioblastoma xenograft - Control 29.12196
GSM967854U87-EV human glioblastoma xenograft - Control 39.2728597
GSM967855U87-EV human glioblastoma xenograft - Control 49.3606697
GSM967856U87-EV human glioblastoma xenograft - Control 59.3551397
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.829896
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 29.0618597
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 39.2416597
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.5190997
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.3215497
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.0926297
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.1058996
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.2198497
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.2121597